We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Ultrasound Contrast Agent Deemed Safe During Stress Echocardiogram

By MedImaging staff writers
Posted on 14 Jul 2008
Recent research has demonstrated that the use of ultrasound contrast agents during stress echocardiograms is safe.

These results, revealed by investigators from the Methodist DeBakey Heart & Vascular Center (Houston, TX, USA) at the 19th annual scientific sessions of the American Society of Echocardiography, held in June 2008, in Toronto, Ontario, Canada, come just months after the U.S. Food and Drug Administration (FDA) mandated a black box warning on the labels of contrast agents used for cardiovascular ultrasound.

The risk of major adverse effects is no different in patients that received contrast during their stress echocardiogram than in those who did not receive contrast, according to research findings. This was evident even though contrast was more frequently used in patients with a higher cardiac risk profile.

"Contrast-enhanced stress echocardiography is a safe option to attain important diagnostic information for patients who need more testing than cardiac ultrasound alone,” said Dr. Kamran Shaikh, postdoctoral echocardiography fellow at the Methodist DeBakey Heart & Vascular Center. "Our research found no link between its use and adverse events or any reason why it shouldn't be available to cardiologists whose patients would benefit from it.”

Contrast, a liquid that is distinctly visible in imaging studies such as echocardiograms, is injected into the heart to enhance the quality of the image. The study examined 3,121 consecutive patients who underwent stress echocardiograms from 2002 through 2007 at the Methodist Hospital (Dallas, TX, USA).

Researchers assessed demographics, contrast use, hemodynamics, electrocardiography (ECG), and wall motion changes, symptoms, and arrhythmias. Contrast was administered in 1,879 of 3,121 patients (60%). None of the patients receiving an ultrasound contrast agent experienced sustained ventricular tachycardia, ventricular fibrillation, cardiac arrest, or death.


Related Links:
Methodist DeBakey Heart & Vascular Center

New
Gold Member
X-Ray QA Meter
T3 AD Pro
Radiology Software
DxWorks
New
Diagnostic Ultrasound System
MS1700C
Imaging Table
CFPM201

Latest Ultrasound News

Wearable Ultrasound Patch Enables Continuous Blood Pressure Monitoring

AI Image-Recognition Program Reads Echocardiograms Faster, Cuts Results Wait Time

Ultrasound Device Non-Invasively Improves Blood Circulation in Lower Limbs